Data Governance for AI in Pharmaceutical Environments

Most AI governance guidance for pharma stops at policy: appoint an owner, write a SOP, log usage. That is necessary but not sufficient. In a GxP setting the harder question is whether your controls are demonstrable to an auditor. This page frames pharmaceutical AI data governance around the three things a reviewer can actually inspect, and lists the concrete evidence a buyer should be able to demand.

The three governance dimensions that matter

Control — where does inference physically execute, and who can reach it? If your model call traverses a third-party API, you have outsourced the boundary. Control means the model runs inside a perimeter you own.

Traceability — can you reconstruct, defensibly, what the model was asked and what it returned, and prove the record was not altered? For regulated work this is the difference between a log and an audit trail.

Residency — do prompts, source documents, and outputs ever leave your environment? Residency is only real when there is no path out, not merely a contractual promise that data will not be retained.

Four verifiable controls to demand as evidence

Governance is stronger when it produces evidence you can check yourself. Hyfstele's deployment exposes four controls, each independently verifiable on the customer's own hardware. Treat this as the checklist to require of any pharma AI vendor.

1. CONTROL 01 — PROVENANCE Weights proven byte-identical to the public artifact

   You can confirm the model running in your perimeter is exactly the open-weight artifact it claims to be — no silent substitution. This is model provenance you verify, not a manifest you accept.

2. CONTROL 02 — LATENT CAPACITY Dormant / latent capacity enumerated

   The model's dormant capacity is enumerated so it is characterized rather than assumed away. This is disclosure of what exists, not a claim that nothing hidden could ever exist.

3. CONTROL 03 — RESIDENCY No egress: no route to the internet, no name to resolve

   Air-gapped operation with no outbound route and no external name to resolve. Things go in, nothing comes out — the residency boundary is enforced by the network, not by policy.

4. CONTROL 04 — TRACEABILITY Every inference anchored to a signed audit chain

   Each inference call is written to a tamper-evident audit chain signed with post-quantum cryptography (ML-DSA). Alterations and gaps are cryptographically detectable.

How no-egress deployment enforces residency

Data residency is the control most often reduced to a contract clause. Hyfstele makes it structural. The model is open-weight and runs inside your own perimeter, air-gapped, with no route to the internet and no external name to resolve. There is no API call leaving the building because there is nowhere for it to go. Prompts, the regulated documents you feed in, and every generated output remain inside the environment you control. That is what makes "no egress" a governance boundary rather than a marketing line: the absence of a path out is verifiable on the hardware, and residency follows from it directly.

The signed audit chain as the traceability backbone

Traceability in a regulated pharma environment has to survive scrutiny. A plain log can be edited; an auditor knows it. Hyfstele anchors every inference call to a tamper-evident audit chain in which each entry is cryptographically linked to the one before it and signed with post-quantum cryptography (ML-DSA). Because the chain is signed and linked, any insertion, deletion, or edit breaks the chain and is detectable. This gives you an attributable, secure, computer-generated record of model activity — the evidentiary backbone that governance depends on and that a Part 11 audit trail expects.

Mapping the controls to your obligations

These mappings describe how the controls support your compliance program. They are inputs to your own validation and qualification; they do not replace it. Read more on 21 CFR Part 11 and AI and GxP AI.

MLR review: governance in a live use case

The clearest application is pharmaceutical MLR (Medical, Legal, Regulatory) promotional review. Hyfstele's assist follows one doctrine: "It flags. You decide." The flow is Flag → Judge → Prove, and there is no LLM inside the flag decision plane — the model surfaces candidates, a human makes the regulatory call, and the audit chain records the proof behind each flag. That separation is itself a governance choice: it keeps accountability with the reviewer while still capturing traceable evidence. You can see it running at mlr.hyfstele.com.

A buyer's governance checklist

Questions to put to any AI vendor before regulated data touches it:

• Can I verify, on my own hardware, that the deployed weights match the public artifact?
• Is the model's dormant capacity enumerated and disclosed to me?
• Is there genuinely no egress — no internet route and no external name to resolve?
• Is every inference written to a signed, tamper-evident audit chain I can inspect?
• Does a human, not the model, own the regulated decision?
• Are all of these evidence I can check, rather than assurances I have to trust?